All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

References

• WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 [cited 2020 Mar 2]. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf
   Google Scholar
• Lemos EV, de La Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663.
   PubMed Web of Science ®Google Scholar
• Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis. 2017;4(3):ofx176.
   PubMedGoogle Scholar
• Maraolo AE, Corcione S, Grossi A, et al. The impact of carbapenem resistance on mortality in patients with Klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Ther. 2021;10(1):541–558.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. The 10 × ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50:1081–1083.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America (IDSA). White Paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012;55(8):1031–1046.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Jezek A, Murray BE, et al. The Infectious Diseases Society of America’s 10 × ‘20 Initiative (10 new systemic antibacterial agents US food and drug administration approved by 2020): is 20 × ‘20 a possibility?. Clin Infect Dis. 2019;69(1):1–11.
   PubMed Web of Science ®Google Scholar
• Kirby T. Europe to boost development of new antimicrobial drugs. Lancet. 2012;379(9833):2229–2230.
   PubMed Web of Science ®Google Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892.
   PubMed Web of Science ®Google Scholar
• Echols R, Ariyasu M, Nagata TD. Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance. Clin Infect Dis. 2019;69(Suppl 7):S559–564.
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–575.
   PubMed Web of Science ®Google Scholar
• Connolly LE, Riddle V, Cebrik D, et al. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018;62(4):e01989–17.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–740.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799.
   PubMed Web of Science ®Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616–2626.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal Infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243.
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). Clin Infect Dis. 2021;73(11):e4539–e4548. DOI:https://doi.org/10.1093/cid/ciaa803.
   PubMed Web of Science ®Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–225.
   PubMed Web of Science ®Google Scholar
• Tabak YP, Sung AH, Ye G, et al. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections. J Hosp Infect. 2019;102(1):37–44.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Welte T, Wunderink RG. Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. Crit Care. 2016;20:19.
   PubMed Web of Science ®Google Scholar
• Skrupky LP, Tellor BR, Mazuski JE. Current strategies for the treatment of complicated intraabdominal infections. Expert Opin Pharmacother. 2013;14(14):1933–1947.
   PubMed Web of Science ®Google Scholar
• FDA. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. Guidance for Industry. 2017. [cited 2021 Apr 14]. Available from: https://www.fda.gov/files/drugs/published/Antibacterial-Therapies-for-Patients-With-an-Unmet-Medical-Need-for-the-Treatment-of-Serious-Bacterial-Diseases.pdf
   Google Scholar
• EMA. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Rev. 3. 2018 [cited 2021 Nov 12]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf
   Google Scholar
• Bassetti M, Ariyasu M, Binkowitz B, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens – the international, multicentre, randomized, open-label, Phase 3 CREDIBLE-CR study. Infect Drug Resist. 2019;12:3607–3623.
   PubMed Web of Science ®Google Scholar
• Paul M, Scudeller L. Clinical research designs to study treatment effects for multidrug-resistant bacteria. Clin Microbiol Infect. 2019;25(8):929–931.
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Rybak MJ. Pathogen-specific clinical trials: a new paradigm in clinical trials for multidrug-resistant organisms. Infect Dis Ther. 2018;7(4):401–405.
   PubMed Web of Science ®Google Scholar
• McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med. 2019;380(8):791–793.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a andomized, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicentre, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–358.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–5601.
   PubMed Web of Science ®Google Scholar
• Ji S, Lv F, Du X, et al. Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection. Int J Infect Dis. 2015;38:108–114.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808.
   PubMed Web of Science ®Google Scholar
• Yahav D, Tau N, Shepshelovich D. Assessment of data supporting the efficacy of new antibiotics for treating infections caused by multidrug-resistant bacteria. Clin Infect Dis. 2021;72(11):1968–1974.
   PubMed Web of Science ®Google Scholar
• Savoldi A, Carrara E, Piddock LJV, et al. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. BMC Infect Dis. 2021;21(1):545.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Schmid A, Wolfensberger A, Nemeth J, et al. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta-analysis. Sci Rep. 2019;9(1):15290.
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Ariyasu M, Takemura M, et al. Cefiderocol treatment for serious infections caused by carbapenem-resistant bacteria: post-hoc analysis of outcomes by pathogen in the CREDIBLE-CR study. Abstract 165. Open Forum Infect Dis. 2020;7(Suppl 1):S212.
   Google Scholar
• Chen Z, Chen Y, Fang Y, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep. 2015;5:17091.
   PubMed Web of Science ®Google Scholar
• Lyu C, Zhang Y, Liu X, et al. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):296.
   PubMed Web of Science ®Google Scholar
• Papst L, Beović B, Pulcini C, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070–1076.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Isler B, Stewart A. New treatment options for multiresistant Gram negatives. Curr Opin Infect Dis. 2020;33(2):214–223.
   PubMed Web of Science ®Google Scholar
• Gniadek TJ, Carroll KC, Simner PJ. Carbapenem-resistant non-glucose-fermenting Gram-negative bacilli: the missing piece to the puzzle. J Clin Microbiol. 2016;54(7):1700–1710.
   PubMed Web of Science ®Google Scholar
• Hsueh SC, Chao CM, Wang CY, et al. Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomised controlled trials. J Glob Antimicrob Resist. 2021;24:376–382.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Outterson K, Engel A, et al. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18(5):275–285.
   PubMed Web of Science ®Google Scholar
• Pew Charitable Trust. Tracking the global pipeline of antibiotics in development. March 2021 [cited 2021 Jul 14]. Available from: https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/tracking-the-global-pipeline-of-antibiotics-in-development
   Google Scholar
• Clinicaltrials.gov. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter baumannii-calcoaceticus complex (ATTACK). [cited 2021 Jul 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03894046
   Google Scholar
• Clinicaltrials.gov. Efficacy, safety, and tolerability of ATM-AVI in the treatment of serious infection due to MBL-producing Gram-negative bacteria. [cited 2021 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03580044
   Google Scholar
• Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005–2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis. 2017;65(1):141–146.
   PubMed Web of Science ®Google Scholar
• Timsit JF, de Kraker MEA, Sommer H, et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Med. 2017;43(7):1002–1012.
   PubMed Web of Science ®Google Scholar
• Farkas J. PulmCrit – chasing mortality endpoints is a fool’s errand. 2018; March 12. [cited 2021 Apr 14]. Available from: https://emcrit.org/pulmcrit/mortality
   Google Scholar
• Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800–806.
   PubMed Web of Science ®Google Scholar
• Weiss E, Zahar J-R, Alder J, et al. Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired/ventilator-associated bacterial pneumonia clinical trials. Clin Infect Dis. 2019;69(11):1912–1918.
   PubMed Web of Science ®Google Scholar
• ECRAID. European clinical research alliance on infectious diseases. [cited 2021 Jul 14]. Available from: https://www.ecraid.eu
   Google Scholar
• COMBACTE. Combatting bacterial resistance in Europe. [cited 2021 Jul 14]. Available from: https://www.combacte.com
   Google Scholar
• Groft LM, Claeys KC, Heil EL. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. Expert Opin Pharmacother. 2021;22(3):265–271.
   PubMed Web of Science ®Google Scholar
• Lanini S, Ioannidis JPA, Vairo F, et al. Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infect Dis. 2019;19(12):e444–e451.
   PubMed Web of Science ®Google Scholar